U.S. health insurer Cigna Corp. will buy pharmacy benefits manager Express Scripts Holding Co., a tie-up that reflects pressure on healthcare companies to grow bigger to cut costs.
Kite Pharma, a Gilead company, inked a worldwide collaboration deal with Sangamo Therapeutics to develop oncology therapeutics.
Enumeral Biomedical filed for bankruptcy protection and is selling its assets to Xoma Corporation for $1.6 million.
AstraZeneca clinched two new deals with Chinese tech giants Alibaba and Tencent as the British drugmaker steps up the company’s drive to expand business in China.
Backed by financing from a collaboration with Novartis and an $83 million financing round, Homology Medicines is moving to a new facility with more than triple the space of its headquarters.
The Trump administration’s tax overhaul should accelerate major acquisitions by drugmakers in 2018, say senior execs from some of the largest manufacturers.
Novo Nordisk A/S has twice made a bid to acquire Ablynx NV, and twice been rejected.
Roche will buy U.S. cancer drugmaker Ignyta Inc. for $1.7 billion to broaden the Swiss drugmaker’s oncology portfolio globally.
Boehringer Ingelheim tied up a schizophrenia drug under development by Autifony Limited, a 2011 spinout of GSK, in a deal that could be worth up to about $740 million.
Belgium-based reMYND’s pre-clinical diabetes therapy ReS39 will get a significant boost after the company entered a licensing agreement with noted European diabetes company Novo Nordisk.